SCHEMBL1016279

SCHEMBL1016279

CC(C)(C)OC(=O)N1CCC(c2ccc(Sc3ccc4[nH]ncc4c3)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.50
PDE4B Q07343 1/20 0.49
GPR119 Q8TDV5 1/20 0.44
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
HPGDS O60760 1/20 0.44
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
FASN P49327 1/20 0.42
TP53 P04637 4/20 0.42
PRMT5 O14744 1/20 0.42
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
PTK2 Q05397 1/20 0.42
ROCK2 O75116 1/20 0.41
MAPT P10636 3/20 0.41
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
LMNA P02545 2/20 0.41
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016278 1.00 PIK3CD (0.50) PIK3CDPDE4BGPR119IDO1TDO2
SCHEMBL1016106 0.85 PIK3CD (0.49) PIK3CDPDE4BGPR119IDO1TDO2
SCHEMBL1016108 0.85 PIK3CD (0.49) PIK3CDPDE4BGPR119IDO1TDO2
SCHEMBL6881915 0.84 PIK3CD (0.54) PIK3CDPDE4BGPR119IDO1TDO2
SCHEMBL22608970 0.84 PDE4B (0.57) PIK3CDPDE4BIDO1TDO2HPGDS
SCHEMBL6881911 0.84 PIK3CD (0.54) PIK3CDPDE4BGPR119IDO1TDO2
SCHEMBL9952336 0.84 FASN (0.52) PIK3CDPDE4BGPR119IDO1TDO2
SCHEMBL3328409 0.82 PIK3CD (0.49) PIK3CDPDE4BIDO1TDO2FASN
SCHEMBL14514349 0.76 ROCK2 (0.63) ROCK2MAPT
SCHEMBL5407903 0.76 PIK3CD (0.56) PIK3CDPDE4BGPR119IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081890-B1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-01-12 EP disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
EP-2081890-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. Hoffmann-Roche AG (CH) 2009-07-29 EP disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 US disclosed
WO-2008055847-A1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors HTR6, HTR1B, HTR1F PIK3CD 3580/4885PDE4B 1026/4885GPR119 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.